Inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) are chronic inflammatory diseases that share immune dysregulation and mitochondrial dysfunction. Understanding the molecular mechanisms linking these diseases to mitochondrial dysfunction is crucial for developing novel diagnostic and therapeutic strategies. Datasets related to IBD and RA were obtained from the Gene Expression Omnibus database. Differentially expressed mitochondrial dysfunction-related genes (MDRGs) were identified using differential expression analysis. Weighted gene co-expression network analysis was performed to identify crosstalk genes (CGs). Logistic regression and support vector machine (SVM) models were constructed using least absolute shrinkage and selection operator regression to identify hub genes. Additionally, the differential expression and diagnostic value of the hub genes were verified using quantitative reverse transcriptase–polymerase chain reaction and validation sets. Finally, immune infiltration analysis was conducted to assess the role of immune cells in IBD and RA. A total of 87 CGs associated with mitochondrial dysfunction were identified between IBD and RA, among which PDIA4 and DUSP6 were identified as hub genes. Twenty proteins, including ERO1A, MAPK7, and P4HB, were identified as key proteins that interacted with PDIA4 and DUSP6. The area under the curve (AUC) of the ROC curves for IBD and RA based on the DUSP6 and PDIA4 diagnostic models were 0.664 and 0.856, respectively. The qRT-PCR results indicated that PDIA4 and DUSP6 were overexpressed in IBD and RA. Seven immune cell types, including activated B cells, activated dendritic cells, and eosinophils showed significant differences in the IBD and RA groups. Our findings highlight the close association between IBD, RA, and mitochondrial dysfunction. PDIA4 and DUSP6 may serve as potential biomarkers of mitochondrial dysfunction in patients with IBD and RA.
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide, underscoring the urgent need for reliable biomarkers and therapeutic targets. To address this need, we focused on UDP-glucose pyrophosphorylase 2 (UGP2). Although UGP2 has been implicated in tumorigenesis across multiple cancers, its precise role and clinical significance in CRC remain poorly understood. This study aimed to comprehensively characterize UGP2 in CRC through an integrated approach encompassing proteomic screening, bioinformatics analysis, and experimental validation. We identified UGP2 as a significantly downregulated tumor-suppressive factor in CRC. Specifically, UGP2 expression was significantly downregulated in CRC tissues compared with that in normal controls and exhibited strong correlations with aggressive clinicopathological features, including lymphatic invasion, perineural invasion, and colon polyp history, and patient age. It also demonstrated high diagnostic accuracy in CRC, with an area under the receiver operating characteristic curve (AUC) of 0.990. Reduced UGP2 levels were associated with poorer overall survival and disease-specific survival. Hypermethylation of the UGP2 promoter correlated with a favorable prognosis in patients with CRC. UGP2 expression positively correlated with immune cell infiltration within the tumor microenvironment. Functionally, UGP2 knockdown increased CRC cell proliferation and migration while suppressing apoptosis. Conversely, its overexpression yielded the opposite effects, confirming UGP2’s role in constraining malignant phenotypes. Collectively, these findings establish UGP2 as a key CRC tumor suppressor whose downregulation drives malignant progression and predicts adverse clinical outcomes, suggesting its potential as a dual-purpose diagnostic and prognostic biomarker.
Our previous studies showed that miR-126 was significantly upregulated in ulcerative colitis (UC) and promoted inflammatory responses by activating the nuclear factor-κB (NF-κB) signalling pathway. This study aimed to explore the transcriptional mechanisms involved in miR-126 upregulation in a cellular inflammation model. miRNA and mRNA expression were measured using qRT-PCR. Protein amounts were measured using western blotting. The core promoter sequences of miR-126 and its host gene EGF-like domain multiple 7 ( EGFL7 ) were determined through a series of plasmid DNA constructions via the luciferase reporter system. The binding of NF-κB3 to the core promoter region of miR-126 was detected using an electrophoretic mobility shift assay. Knockdown of NF-κB3 was performed using siRNA. miR-126 and EGFL7 mRNA were found to be upregulated in UC tissues. However, there was no significant correlation between miR-126 and EGFL7 . In the HT-29 cell line, stimulation of TNFα, IL-1β, lipopolysaccharide, MDP, HKM, and ODN2006 led to a discordant expression pattern of miR-126 and EGFL7 , while IFN-γ or FLA-ST treatment resulted in a concordant expression pattern of miR-126 and EGFL7 . Luciferase activity analysis revealed that miR-126 has its own independent promoter. The upregulated expression and increased phosphorylation of the transcription factor, NF-κB3, were observed in UC tissues. NF-κB3 could directly bind to the core promoter region of miR-126, and regulate the expression of miR-126 and EGFL7 . We demonstrated that miR-126 may have its own independent promoter and could be directly regulated by NF-κB3, partially by its host gene, EGFL7 , and by several molecular modulators. Our study provides further insights into the regulatory mechanisms of the upregulation of miRNA in inflammatory conditions like UC.